To summarize major nanoparticle-based drug delivery systems aimed at altering the tumor immune microenvironment (TIME) in triple-negative breast cancer (TNBC), focusing on specific systems and their mechanisms, and to discuss translational barriers and future directions.
Approach:
Nanocarrier Strategies: The review discusses specific tumor microenvironment (TME)-targeted nanocarriers that exploit features like hypoxia, acidity, and abnormal vascular cues to enhance therapy efficacy.
Therapeutic Strategies: It highlights the use of these specific nanocarriers in conjunction with therapies such as immune checkpoint blockade.
Translational Barriers: The article identifies specific barriers such as TIME heterogeneity, enhanced permeability and retention (EPR) effect, and protein corona formation.
Future Development: It advocates for patient stratification and simplified nanocarrier designs to support precision treatment.
Key Findings:
TIME is crucial in determining tumor immunogenicity and response to therapy.
TNBC is particularly challenging due to its lack of specific targets and high heterogeneity.
Specific nanoparticle-based systems can enhance the efficacy of immunotherapies by targeting the TME.
Interpretation:
The review emphasizes the need for innovative drug delivery systems that can effectively alter the TIME in TNBC.
Limitations:
The complexity of TIME and its heterogeneity presents significant challenges for nanoparticle-based therapies.
Current nanocarrier designs may not be sufficiently reproducible or clinically applicable.
Conclusion:
Future research should focus on integrating patient stratification and developing simplified nanocarrier designs for effective TNBC treatment.
